FdaApplication
BLA 761320
Identifiers
- fda_app_no: BLA761320
Properties
| Property | Value |
|---|---|
| applicant_name | Outlook Therapeutics, Inc. |
| application_type | BLA |
| approval_date | 2026-07-24 |
Revenue by product
LYTENAVA
| Period | Revenue |
|---|---|
| Q3 2025 | $-0.1M† |
| Q2 2025 | $1.5M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| LYTENAVA | BEVACIZUMAB-VIKG | 1.25MG (0.05ML of 25MG/ML) | Injection |
1 product